Translate Bio Resumes Enrollment and Dosing in Phase 1/2 Clinical Trial of MRT5005 in Cystic Fibrosis
September 08, 2020 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Second Quarter 2020 Financial Results and Reviews Recent Progress
August 06, 2020 16:14 ET
|
Translate Bio, Inc.
-- Expanded collaboration with partner Sanofi Pasteur for all infectious diseases further unites Translate Bio’s leading mRNA technology and large-scale manufacturing with Sanofi’s world class vaccine...
Translate Bio Provides MRT5005 Program Updates
March 26, 2020 16:30 ET
|
Translate Bio, Inc.
-- FDA grants Rare Pediatric Disease designation for MRT5005 for treatment of cystic fibrosis – -- Response to COVID-19 pandemic anticipated to cause interruptions in certain clinical trial...
Translate Bio Receives FDA Fast Track Designation for MRT5005 for the Treatment of Cystic Fibrosis
February 26, 2020 07:30 ET
|
Translate Bio, Inc.
-- First inhaled mRNA therapeutic remains on track to report results from its ongoing multiple-ascending dose (MAD) portion of Phase 1/2 clinical trial in the third quarter of 2020 -- LEXINGTON,...
Abeona Therapeutics Announces Presentations at the 27th European Society of Gene and Cell Therapy (ESGCT) Congress
October 21, 2019 09:15 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the presentations of data from...
Translate Bio Announces Upcoming MRT5005 Presentations at the 33rd Annual North American Cystic Fibrosis Conference
October 01, 2019 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Claire’s Place Foundation Welcomes New Board Members
June 26, 2019 09:00 ET
|
Claire's Place Foundation
Los Angeles, CA, June 26, 2019 (GLOBE NEWSWIRE) -- Claire’s Place Foundation, a non-profit organization providing support to children and families affected by cystic fibrosis, welcomes Richard K....
Abeona Therapeutics to Report New Preclinical Data Demonstrating Therapeutic Potential of ABO-401 for Treatment of Cystic Fibrosis at American Society of Gene and Cell Therapy Annual Meeting
April 30, 2019 08:00 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, April 30, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today will report new preclinical data...
Claire’s Place Foundation Assists Over 150 Families with Cystic Fibrosis
December 12, 2018 09:00 ET
|
Claire's Place Foundation
Los Angeles, CA, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Claire’s Place Foundation, a non-profit organization providing support to children and families affected by cystic fibrosis (CF), is proud to...
Results from Celtaxsys’ Acebilustat Phase 2 Trial in Cystic Fibrosis Patients Showing Clinically Meaningful Improvement in Pulmonary Exacerbations Presented at the North American Cystic Fibrosis Conference
October 22, 2018 08:00 ET
|
Celtaxsys, Inc.
ATLANTA, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, today...